Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $225 | $58 | $60 | $77 |
| Short-Term Investments | $119 | $123 | $144 | $99 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $6 | $12 | $12 |
| Total Curr. Assets | $353 | $187 | $216 | $189 |
| Property Plant & Equip (Net) | $6 | $6 | $2 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $1 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $0 | $1 | $1 |
| Total NC Assets | $9 | $8 | $4 | $4 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $363 | $195 | $220 | $194 |
| Liabilities | – | – | – | – |
| Payables | $5 | $3 | $5 | $3 |
| Short-Term Debt | $1 | $1 | $1 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $19 | $17 | $12 | $24 |
| Total Curr. Liab. | $26 | $21 | $18 | $28 |
| LT Debt | $5 | $5 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $5 | $5 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $5 | $6 | $1 | $2 |
| Total Liabilities | $31 | $27 | $18 | $29 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$718 | -$684 | -$643 | -$607 |
| AOCI | $1 | $1 | $0 | -$0 |
| Other Equity | $1,050 | $851 | $844 | $772 |
| Total Equity | $332 | $168 | $201 | $165 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $363 | $195 | $220 | $194 |
| Net Debt | -$219 | -$52 | -$58 | -$75 |